Boehringer envisagenics sign 1b multi target oncology collaboration

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 24 Sept, 12:07 UTC

Boehringer Ingelheim and AI drug discovery company Envisagenics have agreed to a potential $1 billion multi-year pact that will task Boehringer with validating tumor-specific targets.